Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma

OBJECTIVE: The aim of this study is to compare gemcitabine (G) plus docetaxel (D) versus G plus anlotinib (A) for advanced soft tissue sarcoma (STS). METHODS: We retrospectively investigated 122 patients with locally advanced or metastatic STS who were treated with either G+D or G+A between July 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhiyong, Wang, Xin, Wang, Jiaqiang, Zhang, Peng, Li, Chao, Wang, Bangmin, Liu, Guancong, Yao, Weitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326030/
https://www.ncbi.nlm.nih.gov/pubmed/35912272
http://dx.doi.org/10.3389/fonc.2022.922127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326030/
https://www.ncbi.nlm.nih.gov/pubmed/35912272
http://dx.doi.org/10.3389/fonc.2022.922127

Ejemplares similares